Skip to main content
Erschienen in: Endocrine 3/2016

28.07.2016 | Original Article

TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells by inhibiting RhoA/ROCK signaling

verfasst von: Fengxiao Xiong, Xuejuan Li, Zhiying Yang, Yu Wang, Wenyan Gong, Junying Huang, Cheng Chen, Peiqing Liu, Heqing Huang

Erschienen in: Endocrine | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

RhoA/ROCK can cause renal inflammation and fibrosis in the context of diabetes by activating nuclear factor-κB (NF-κB). TGR5 is known for its role in maintaining metabolic homeostasis and anti-inflammation, which is closely related to NF-κB inhibition. Given that TGR5 is highly enriched in kidney, we aim to investigate the regulatory role of TGR5 on fibronectin (FN) and transforming growth factor-β1 (TGF-β1) in high glucose (HG)-treated rat glomerular mesangial cells (GMCs). Both the factors are closely related to renal inflammations and mediated by NF-κB. Moreover, our study determines whether such regulation is achieved by the inhibition of RhoA/ROCK and the subsequent NF-κB suppression. Polymerase chain reaction was taken to test the mRNA level of TGR5. Western blot was used to measure the protein expressions of TGR5, FN, TGF-β1, p65, IκBα, phospho-MYPT1 (Thr853), and MYPT1. Glutathione S-transferase-pull down and immunofluorescence were conducted to test the activation of RhoA, the distribution of TGR5, and p65, respectively. Electrophoretic mobility shift assay was adopted to measure the DNA binding activity of NF-κB. In GMCs, TGR5 activation or overexpression significantly suppressed FN and TGF-β1 protein expressions, NF-κB, and RhoA/ROCK activation induced by HG or transfection of constitutively active RhoA. By contrast, TGR5 RNA interference caused enhancement of FN, TGF-β1 protein expressions, increase of RhoA/ROCK activation. However, TGR5 cannot suppress RhoA/ROCK activation when a selective Protein kinase A (PKA) inhibitor was used. This study suggests that in HG-treated GMCs, TGR5 significantly suppresses the NF-κB-mediated upregulation of FN and TGF-β1, which are hallmarks of diabetic nephropathy. These functions are closely related to the suppression of RhoA/ROCK via PKA.
Literatur
1.
Zurück zum Zitat Y.S. Kanwar, L. Sun, P. Xie, F.Y. Liu, S. Chen, A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6, 395–423 (2011)CrossRefPubMedPubMedCentral Y.S. Kanwar, L. Sun, P. Xie, F.Y. Liu, S. Chen, A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6, 395–423 (2011)CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat C. Ponchiardi, M. Mauer, B. Najafian, Temporal profile of diabetic nephropathy pathologic changes. Curr. Diab. Rep. 13(4), 592–599 (2013)CrossRefPubMed C. Ponchiardi, M. Mauer, B. Najafian, Temporal profile of diabetic nephropathy pathologic changes. Curr. Diab. Rep. 13(4), 592–599 (2013)CrossRefPubMed
3.
Zurück zum Zitat A. Cove-Smith, H. BM, The regulation of mesangial cell proliferation. Nephron. Exp. Nephrol. 108(4), e74–e79 (2008)CrossRefPubMed A. Cove-Smith, H. BM, The regulation of mesangial cell proliferation. Nephron. Exp. Nephrol. 108(4), e74–e79 (2008)CrossRefPubMed
5.
Zurück zum Zitat J.F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros de Fuentes, J. Garcia-Perez, Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7(6), 327–340 (2011)CrossRefPubMed J.F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros de Fuentes, J. Garcia-Perez, Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7(6), 327–340 (2011)CrossRefPubMed
6.
Zurück zum Zitat K.I. Woroniecka, A.S. Park, D. Mohtat, D.B. Thomas, J.M. Pullman, K. Susztak, Transcriptome analysis of human diabetic kidney disease. Diabetes 60(9), 2354–2369 (2011)CrossRefPubMedPubMedCentral K.I. Woroniecka, A.S. Park, D. Mohtat, D.B. Thomas, J.M. Pullman, K. Susztak, Transcriptome analysis of human diabetic kidney disease. Diabetes 60(9), 2354–2369 (2011)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat I.A. Bondar’, V.V. Klimontov, A.P. Nadeev, Urinary excretion of proinflammatory cytokines and transforming growth factor beta at early stages of diabetic nephropathy. Ter. Arkh. 80(1), 52–56 (2008)PubMed I.A. Bondar’, V.V. Klimontov, A.P. Nadeev, Urinary excretion of proinflammatory cytokines and transforming growth factor beta at early stages of diabetic nephropathy. Ter. Arkh. 80(1), 52–56 (2008)PubMed
8.
Zurück zum Zitat A.P. Sanchez, K. Sharma, Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 11, e13 (2009)CrossRefPubMed A.P. Sanchez, K. Sharma, Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 11, e13 (2009)CrossRefPubMed
9.
Zurück zum Zitat H. Schmid, A. Boucherot, Y. Yasuda, A. Henger, B. Brunner, F. Eichinger, A. Nitsche, E. Kiss, M. Bleich, H.J. Grone, P.J. Nelson, D. Schlondorff, C.D. Cohen, M. Kretzler; European Renal c, D.N.A.B.C., Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55(11), 2993–3003 (2006)CrossRefPubMed H. Schmid, A. Boucherot, Y. Yasuda, A. Henger, B. Brunner, F. Eichinger, A. Nitsche, E. Kiss, M. Bleich, H.J. Grone, P.J. Nelson, D. Schlondorff, C.D. Cohen, M. Kretzler; European Renal c, D.N.A.B.C., Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55(11), 2993–3003 (2006)CrossRefPubMed
10.
Zurück zum Zitat S. Mezzano, C. Aros, A. Droguett, M.E. Burgos, L. Ardiles, C. Flores, H. Schneider, M. Ruiz-Ortega, J. Egido, NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19(10), 2505–2512 (2004)CrossRefPubMed S. Mezzano, C. Aros, A. Droguett, M.E. Burgos, L. Ardiles, C. Flores, H. Schneider, M. Ruiz-Ortega, J. Egido, NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19(10), 2505–2512 (2004)CrossRefPubMed
11.
Zurück zum Zitat Y. Kawamata, R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, M. Fujino, A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278(11), 9435–9440 (2003)CrossRefPubMed Y. Kawamata, R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, M. Fujino, A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278(11), 9435–9440 (2003)CrossRefPubMed
12.
Zurück zum Zitat T. Maruyama, Y. Miyamoto, T. Nakamura, Y. Tamai, H. Okada, E. Sugiyama, T. Nakamura, H. Itadani, K. Tanaka, Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298(5), 714–719 (2002)CrossRefPubMed T. Maruyama, Y. Miyamoto, T. Nakamura, Y. Tamai, H. Okada, E. Sugiyama, T. Nakamura, H. Itadani, K. Tanaka, Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298(5), 714–719 (2002)CrossRefPubMed
13.
Zurück zum Zitat T.W. Pols, L.G. Noriega, M. Nomura, J. Auwerx, K. Schoonjans, The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 54(6), 1263–1272 (2011)CrossRefPubMed T.W. Pols, L.G. Noriega, M. Nomura, J. Auwerx, K. Schoonjans, The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 54(6), 1263–1272 (2011)CrossRefPubMed
14.
Zurück zum Zitat K.L. Pierce, R.T. Premont, R.J. Lefkowitz, Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3(9), 639–650 (2002)CrossRefPubMed K.L. Pierce, R.T. Premont, R.J. Lefkowitz, Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3(9), 639–650 (2002)CrossRefPubMed
15.
Zurück zum Zitat C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167–177 (2009)CrossRefPubMedPubMedCentral C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167–177 (2009)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat M. Watanabe, S.M. Houten, C. Mataki, M.A. Christoffolete, B.W. Kim, H. Sato, N. Messaddeq, J.W. Harney, O. Ezaki, T. Kodama, K. Schoonjans, A.C. Bianco, J. Auwerx, Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484–489 (2006)CrossRefPubMed M. Watanabe, S.M. Houten, C. Mataki, M.A. Christoffolete, B.W. Kim, H. Sato, N. Messaddeq, J.W. Harney, O. Ezaki, T. Kodama, K. Schoonjans, A.C. Bianco, J. Auwerx, Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484–489 (2006)CrossRefPubMed
17.
Zurück zum Zitat T.W. Pols, M. Nomura, T. Harach, G. Lo Sasso, M.H. Oosterveer, C. Thomas, G. Rizzo, A. Gioiello, L. Adorini, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14(6), 747–757 (2011)CrossRefPubMedPubMedCentral T.W. Pols, M. Nomura, T. Harach, G. Lo Sasso, M.H. Oosterveer, C. Thomas, G. Rizzo, A. Gioiello, L. Adorini, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14(6), 747–757 (2011)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Y.D. Wang, W.D. Chen, D. Yu, B.M. Forman, W. Huang, The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54(4), 1421–1432 (2011)CrossRefPubMedPubMedCentral Y.D. Wang, W.D. Chen, D. Yu, B.M. Forman, W. Huang, The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54(4), 1421–1432 (2011)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat C. Guo, H. Qi, Y. Yu, Q. Zhang, J. Su, D. Yu, W. Huang, W.D. Chen, Y.D. Wang, The G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-kappaB signaling pathway. Front. Pharmacol. 6, 287 (2015)CrossRefPubMedPubMedCentral C. Guo, H. Qi, Y. Yu, Q. Zhang, J. Su, D. Yu, W. Huang, W.D. Chen, Y.D. Wang, The G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-kappaB signaling pathway. Front. Pharmacol. 6, 287 (2015)CrossRefPubMedPubMedCentral
20.
21.
Zurück zum Zitat T. Matsui, M. Amano, T. Yamamoto, K. Chihara, M. Nakafuku, M. Ito, T. Nakano, K. Okawa, A. Iwamatsu, K. Kaibuchi, Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15(9), 2208–2216 (1996)PubMedPubMedCentral T. Matsui, M. Amano, T. Yamamoto, K. Chihara, M. Nakafuku, M. Ito, T. Nakano, K. Okawa, A. Iwamatsu, K. Kaibuchi, Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15(9), 2208–2216 (1996)PubMedPubMedCentral
22.
Zurück zum Zitat H. Zhou, Y. Li, Long-term diabetic complications may be ameliorated by targeting Rho kinase. Diabetes Metab. Res. Rev. 27(4), 318–330 (2011)CrossRefPubMed H. Zhou, Y. Li, Long-term diabetic complications may be ameliorated by targeting Rho kinase. Diabetes Metab. Res. Rev. 27(4), 318–330 (2011)CrossRefPubMed
23.
Zurück zum Zitat E. Amin, B.N. Dubey, S.C. Zhang, L. Gremer, R. Dvorsky, J.M. Moll, M.S. Taha, L. Nagel-Steger, R.P. Piekorz, A.V. Somlyo, M.R. Ahmadian, Rho-kinase: regulation, (dys)function, and inhibition. Biol. Chem. 394(11), 1399–1410 (2013)CrossRefPubMed E. Amin, B.N. Dubey, S.C. Zhang, L. Gremer, R. Dvorsky, J.M. Moll, M.S. Taha, L. Nagel-Steger, R.P. Piekorz, A.V. Somlyo, M.R. Ahmadian, Rho-kinase: regulation, (dys)function, and inhibition. Biol. Chem. 394(11), 1399–1410 (2013)CrossRefPubMed
24.
Zurück zum Zitat F. Peng, D. Wu, B. Gao, A.J. Ingram, B. Zhang, K. Chorneyko, R. McKenzie, J.C. Krepinsky, RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57(6), 1683–1692 (2008)CrossRefPubMed F. Peng, D. Wu, B. Gao, A.J. Ingram, B. Zhang, K. Chorneyko, R. McKenzie, J.C. Krepinsky, RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57(6), 1683–1692 (2008)CrossRefPubMed
25.
Zurück zum Zitat V. Kolavennu, L. Zeng, H. Peng, Y. Wang, F.R. Danesh, Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57(3), 714–723 (2008)CrossRefPubMed V. Kolavennu, L. Zeng, H. Peng, Y. Wang, F.R. Danesh, Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57(3), 714–723 (2008)CrossRefPubMed
26.
Zurück zum Zitat X. Xie, J. Peng, X. Chang, K. Huang, J. Huang, S. Wang, X. Shen, P. Liu, H. Huang, Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol. Cell. Endocrinol. 369(1–2), 86–97 (2013)CrossRefPubMed X. Xie, J. Peng, X. Chang, K. Huang, J. Huang, S. Wang, X. Shen, P. Liu, H. Huang, Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol. Cell. Endocrinol. 369(1–2), 86–97 (2013)CrossRefPubMed
27.
Zurück zum Zitat A. Gojo, K. Utsunomiya, K. Taniguchi, T. Yokota, S. Ishizawa, Y. Kanazawa, H. Kurata, N. Tajima, The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 568(1–3), 242–247 (2007)CrossRefPubMed A. Gojo, K. Utsunomiya, K. Taniguchi, T. Yokota, S. Ishizawa, Y. Kanazawa, H. Kurata, N. Tajima, The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 568(1–3), 242–247 (2007)CrossRefPubMed
28.
Zurück zum Zitat R. Komers, T.T. Oyama, D.R. Beard, C. Tikellis, B. Xu, D.F. Lotspeich, S. Anderson, Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int. 79(4), 432–442 (2011)CrossRefPubMed R. Komers, T.T. Oyama, D.R. Beard, C. Tikellis, B. Xu, D.F. Lotspeich, S. Anderson, Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int. 79(4), 432–442 (2011)CrossRefPubMed
29.
Zurück zum Zitat R. Samarakoon, S.P. Higgins, C.E. Higgins, P.J. Higgins, TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J. Mol. Cell. Cardiol. 44(3), 527–538 (2008)CrossRefPubMedPubMedCentral R. Samarakoon, S.P. Higgins, C.E. Higgins, P.J. Higgins, TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J. Mol. Cell. Cardiol. 44(3), 527–538 (2008)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat H. Shimada, L.E. Rajagopalan, Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. J. Biol. Chem. 285(17), 12536–12542 (2010)CrossRefPubMedPubMedCentral H. Shimada, L.E. Rajagopalan, Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. J. Biol. Chem. 285(17), 12536–12542 (2010)CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat H. Iwasaki, R. Okamoto, S. Kato, K. Konishi, H. Mizutani, N. Yamada, N. Isaka, T. Nakano, M. Ito, High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196(1), 22–28 (2008)CrossRefPubMed H. Iwasaki, R. Okamoto, S. Kato, K. Konishi, H. Mizutani, N. Yamada, N. Isaka, T. Nakano, M. Ito, High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196(1), 22–28 (2008)CrossRefPubMed
32.
Zurück zum Zitat K. Geoffroy, N.M. Wiernsperger, B.S. El, Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 279(33), 34343–34352 (2004)CrossRefPubMed K. Geoffroy, N.M. Wiernsperger, B.S. El, Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 279(33), 34343–34352 (2004)CrossRefPubMed
33.
Zurück zum Zitat M.C. Subauste, M. Von Herrath, V. Benard, C.E. Chamberlain, T.H. Chuang, K. Chu, G.M. Bokoch, K.M. Hahn, Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 275(13), 9725–9733 (2000)CrossRefPubMed M.C. Subauste, M. Von Herrath, V. Benard, C.E. Chamberlain, T.H. Chuang, K. Chu, G.M. Bokoch, K.M. Hahn, Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J. Biol. Chem. 275(13), 9725–9733 (2000)CrossRefPubMed
34.
Zurück zum Zitat Q. Jiang, P. Liu, X. Wu, W. Liu, X. Shen, T. Lan, S. Xu, J. Peng, X. Xie, H. Huang, Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 331(1), 34–40 (2011)CrossRefPubMed Q. Jiang, P. Liu, X. Wu, W. Liu, X. Shen, T. Lan, S. Xu, J. Peng, X. Xie, H. Huang, Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 331(1), 34–40 (2011)CrossRefPubMed
35.
Zurück zum Zitat Y. Rikitake, J.K. Liao, Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111(24), 3261–3268 (2005)CrossRefPubMedPubMedCentral Y. Rikitake, J.K. Liao, Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111(24), 3261–3268 (2005)CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat T. Lan, X. Shen, P. Liu, W. Liu, S. Xu, X. Xie, Q. Jiang, W. Li, H. Huang, Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch. Biochem. Biophys. 502(2), 112–120 (2010)CrossRefPubMed T. Lan, X. Shen, P. Liu, W. Liu, S. Xu, X. Xie, Q. Jiang, W. Li, H. Huang, Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch. Biochem. Biophys. 502(2), 112–120 (2010)CrossRefPubMed
37.
Zurück zum Zitat Y.X. Tao, Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol. Ther. 120(2), 129–148 (2008)CrossRefPubMedPubMedCentral Y.X. Tao, Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol. Ther. 120(2), 129–148 (2008)CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat R. Seifert, K. Wenzel-Seifert, Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366(5), 381–416 (2002)CrossRefPubMed R. Seifert, K. Wenzel-Seifert, Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366(5), 381–416 (2002)CrossRefPubMed
39.
Zurück zum Zitat A.B. Sanz, M.D. Sanchez-Nino, A.M. Ramos, J.A. Moreno, B. Santamaria, M. Ruiz-Ortega, J. Egido, A. Ortiz, NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 21(8), 1254–1262 (2010)CrossRefPubMed A.B. Sanz, M.D. Sanchez-Nino, A.M. Ramos, J.A. Moreno, B. Santamaria, M. Ruiz-Ortega, J. Egido, A. Ortiz, NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 21(8), 1254–1262 (2010)CrossRefPubMed
40.
Zurück zum Zitat T. Ishizaki, M. Uehata, I. Tamechika, J. Keel, K. Nonomura, M. Maekawa, S. Narumiya, Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57(5), 976–983 (2000)PubMed T. Ishizaki, M. Uehata, I. Tamechika, J. Keel, K. Nonomura, M. Maekawa, S. Narumiya, Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57(5), 976–983 (2000)PubMed
41.
Zurück zum Zitat T. Chijiwa, A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, H. Hidaka, Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265(9), 5267–5272 (1990)PubMed T. Chijiwa, A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, H. Hidaka, Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265(9), 5267–5272 (1990)PubMed
43.
44.
Zurück zum Zitat F.G. Schaap, M. Trauner, P.L. Jansen, Bile acid receptors as targets for drug development. Nat. Rev. Gastrol. Hepatol. 11(1), 55–67 (2014)CrossRef F.G. Schaap, M. Trauner, P.L. Jansen, Bile acid receptors as targets for drug development. Nat. Rev. Gastrol. Hepatol. 11(1), 55–67 (2014)CrossRef
45.
Zurück zum Zitat V. Stepanov, K. Stankov, M. Mikov, The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J. Recept. Signal Transduct. Res. 33(4), 213–223 (2013)CrossRefPubMed V. Stepanov, K. Stankov, M. Mikov, The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J. Recept. Signal Transduct. Res. 33(4), 213–223 (2013)CrossRefPubMed
46.
Zurück zum Zitat R. Pellicciari, A. Gioiello, A. Macchiarulo, C. Thomas, E. Rosatelli, B. Natalini, R. Sardella, M. Pruzanski, A. Roda, E. Pastorini, K. Schoonjans, J. Auwerx, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52(24), 7958–7961 (2009)CrossRefPubMed R. Pellicciari, A. Gioiello, A. Macchiarulo, C. Thomas, E. Rosatelli, B. Natalini, R. Sardella, M. Pruzanski, A. Roda, E. Pastorini, K. Schoonjans, J. Auwerx, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52(24), 7958–7961 (2009)CrossRefPubMed
47.
Zurück zum Zitat X. Chen, G. Lou, Z. Meng, W. Huang, TGR5: a novel target for weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011, 853501 (2011)PubMedPubMedCentral X. Chen, G. Lou, Z. Meng, W. Huang, TGR5: a novel target for weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011, 853501 (2011)PubMedPubMedCentral
48.
Zurück zum Zitat X.X. Wang, M.H. Edelstein, U. Gafter, L. Qiu, Y. Luo, E. Dobrinskikh, S. Lucia, L. Adorini, V.D. D'Agati, J. Levi, A. Rosenberg, J.B. Kopp, D.R. Gius, M.A. Saleem, M. Levi, protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes. J. Am. Soc. Nephrol. (2015). X.X. Wang, M.H. Edelstein, U. Gafter, L. Qiu, Y. Luo, E. Dobrinskikh, S. Lucia, L. Adorini, V.D. D'Agati, J. Levi, A. Rosenberg, J.B. Kopp, D.R. Gius, M.A. Saleem, M. Levi, protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes. J. Am. Soc. Nephrol. (2015).
49.
Zurück zum Zitat P. Lang, F. Gesbert, M. Delespine-Carmagnat, R. Stancou, M. Pouchelet, J. Bertoglio, Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 15(3), 510–519 (1996)PubMedPubMedCentral P. Lang, F. Gesbert, M. Delespine-Carmagnat, R. Stancou, M. Pouchelet, J. Bertoglio, Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 15(3), 510–519 (1996)PubMedPubMedCentral
50.
Zurück zum Zitat S. Rajagopal, D.P. Kumar, S. Mahavadi, S. Bhattacharya, R. Zhou, C.U. Corvera, N.W. Bunnett, J.R. Grider, K.S. Murthy, Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 304(5), G527–G535 (2013)CrossRefPubMed S. Rajagopal, D.P. Kumar, S. Mahavadi, S. Bhattacharya, R. Zhou, C.U. Corvera, N.W. Bunnett, J.R. Grider, K.S. Murthy, Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 304(5), G527–G535 (2013)CrossRefPubMed
Metadaten
Titel
TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells by inhibiting RhoA/ROCK signaling
verfasst von
Fengxiao Xiong
Xuejuan Li
Zhiying Yang
Yu Wang
Wenyan Gong
Junying Huang
Cheng Chen
Peiqing Liu
Heqing Huang
Publikationsdatum
28.07.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1032-4

Weitere Artikel der Ausgabe 3/2016

Endocrine 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.